CONMED Corporation (CNMD)

Surgical device maker, 62% in operations. Read November 8, 2026 from the annual report for the period ending December 31, 2025, filed February 17, 2026. Ranked 110 of the 145 Healthcare companies read so far, by the share within reach now.

CONMED states about 3,900 full-time employees, 2,400 of them in operations at three manufacturing locations, making surgical devices read whole at medical equipment and supplies manufacturing.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 29% now, 36% at the end of 2027, 38% at the end of 2028, 38% at the end of 2030. By the patterns, the work is about 38% desk work, 16% people work and 46% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 57% of the working time stays with people (conversation, in-person and hands-on work), 36% becomes checking a model's work and 6% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

3,900 employees as of December 31, 2025 (stated). The filing states no count by country; three primary manufacturing locations and distribution worldwide; 56% of revenue in the United States by the data service.

The filing: “As of December 31, 2025, we had approximately 3,900 full-time employees, including approximately 2,400 in operations and the remaining in sales, marketing, research and development and administration.”

The workforce as industry patterns

What the filing says about the workforce: About 3,900 full-time employees, about 2,400 in operations (62%) and the rest in sales, marketing, research and development and administration; three primary manufacturing locations; headquarters in Largo, Florida; no union or country counts.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Medical Equipment and Supplies Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five. Now is projected from METR's April 2026 measurement and Epoch's November 2026 index.

• Abbott Laboratories (ABT, 115,000 employees)28% now, 37% by 2028
• Becton, Dickinson and Company (BDX, 72,000 employees)29% now, 38% by 2028
• Boston Scientific Corporation (BSX, 59,000 employees)32% now, 44% by 2028
• Stryker Corporation (SYK, 56,000 employees)30% now, 41% by 2028
• Baxter International Inc. (BAX, 37,500 employees)30% now, 39% by 2028
• Align Technology, Inc. (ALGN, 20,290 employees)29% now, 38% by 2028
• Solventum Corporation (SOLV, 20,000 employees)33% now, 45% by 2028
• STERIS plc (STE, 17,937 employees)33% now, 41% by 2028

What the filing says about AI

7 sentences in the filing name AI. The filing says it has begun to deploy AI and other emerging technologies in various facets of its operations and continues to explore use cases, and names the risks that AI-generated content could be deficient or competitors adopt AI faster, in seven sentences.

• “We will also update and implement new software of information technology from time to time and any material disruptions, delays or deficiencies in the design and implementation of such updated or new technology may have an adverse affect on our operations and operating results. 18 Our use of artificial intelligence ("AI") and other emerging technologies could adversely impact our business and f...”
• “We have begun to deploy AI and other emerging technologies in various facets of our operations, and we continue to explore further use cases.”
• “The rapid advancement of these technologies presents opportunities for us in research, manufacturing, commercialization, and other business endeavors, but also entails risks, including that AI-generated content, analyses, or recommendations we utilize could be deficient, that our competitors may more quickly or effectively adopt AI capabilities, or that our use of AI or other emerging technolog...”
• “In addition, any disruption or failure in the AI functionality we incorporate into our business activities, products or services could adversely impact our business or result in delays or errors in our product offerings.”
• “The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain, including in the areas of intellectual property, cybersecurity and privacy and data protection.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20230median 1
• Fiscal 20240median 4
• Fiscal 20257median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• No count by country is stated; the U.S. share is left null.

Source: the company's annual report on EDGAR, accession 0000816956-26-000009, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.